Researchers unlock new mechanism in pain management
Complete the form below to unlock access to ALL audio articles.
It’s in the brain where we perceive the unpleasant sensations of pain, and researchers have long been examining how calcium channels in the brain and peripheral nervous system contribute to the development of chronic pain conditions.
Neuroscientist Gerald Zamponi, PhD, and his team at the University of Calgary’s Hotchkiss Brain Institute have discovered a new mechanism that can reverse chronic pain. Using an animal model, their research has found that pain signals in nerve cells can be shut off by interfering with the communication of a specific enzyme with calcium channels, a group of important proteins that control nerve impulses.
Their Canadian Institutes of Health Research-funded study was published in the September issue of Neuron — one of the most influential journals in the field of neuroscience.
Zamponi is now applying his research and partnering with the Centre for Drug Research and Development (CDRD) in Vancouver to develop a drug that could one day improve the lives of those with inflammatory pain such as arthritis, irritable bowel disease or neuropathic pain. Their approach may be able to reduce the pain associated with these conditions.
Opening the door to new treatments
“Chronic pain can be a debilitating condition that affects many people and is often poorly controlled by currently available treatments. Therefore, new treatment avenues are needed. Our discovery opens the door towards new treatments, and based on the data that we have so far, it is a viable strategy,” says Zamponi, the lead author of the study and senior associate dean of research at the Cumming School of Medicine.
With CDRD, Zamponi and his team are screening more than 100,000 molecules in hopes of finding one that would stop the enzyme from communicating with the calcium channel. If they can isolate the right molecule, they can potentially turn it into a drug. So far, they have already found two viable molecules that have been validated by his group as painkillers in animals.
Promising innovation from basic research
Commercialization of the project Zamponi and his team are working on is one of six funded through the competition of the Alberta/Pfizer Translational Research Fund Opportunity. “AIHS is delighted that the strong partnership created with Pfizer, Western Economic Diversification, and Alberta Innovation and Advanced Education is helping to develop promising innovations from basic research into technologies, drugs, and tools to improve health,” says Dr. Cy Frank, president and CEO of Alberta Innovates – Health Solutions.
The Alberta/Pfizer Translational Research Fund Opportunity is a partnership between Pfizer Canada Inc., Alberta Innovates – Health Solutions, Alberta’s Ministry of Innovation and Advanced Education, and Western Economic Diversification Canada. This partnership will provide opportunities to focus on the development and commercialization of innovations in health. More than $3.25 million has been committed to identify and support promising health-care innovations with market potential.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
University of Calgary Original reporting by: Marta Cyperling
Publication
Agustin García-Caballero, Vinicius M. Gadotti, Patrick Stemkowski, Norbert Weiss, Ivana A. Souza, Victoria Hodgkinson, Chris Bladen, Lina Chen, Jawed Hamid, Anne Pizzoccaro, Mickael Deage, Amaury François, Emmanuel Bourinet, Gerald W. Zamponi. The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity. Neuron, Published Online September 3 2014. doi: 10.1016/j.neuron.2014.07.036
